A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Complete Title: A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Trial Phase: I/II

Investigator: Mazyar Shadman

Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts)

Keywords:

Leukemia, Chronic Lymphocytic (CLL)
B-Cell Malignancies
Waldenstrom Macroglobulinemia
Lymphoma, Mantle-Cell
Lymphoma, Follicular
Lymphoma, Small Lymphocytic (SLL)
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell Non-Hodgkin
Lymphoma, Marginal Zone

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.